Medindia

X

Bionovo Adds Dr. James H. Pickar, Former Executive at Wyeth, to Medical Advisory Board

Wednesday, August 11, 2010 Corporate News J E 4
Advertisement


EMERYVILLE, Calif., Aug. 11 Bionovo, Inc. (Nasdaq: BNVI) announced today the appointment of James H. Pickar, M.D. to the company's Medical Advisory Board. Dr. Pickar is a world renowned leader and researcher in the area of women's health.

"We are honored to have one of the world's foremost authorities in the area of women's health join our Medical Advisory Board. Dr. Pickar's 25 years of industry experience in clinical development at Wyeth will be an extraordinary asset to Bionovo as we advance Menerba through late stage clinical testing and drug approval. Dr. Pickar has extensive experience in designing and conducting multinational clinical trials for the treatment of postmenopausal hot flashes and he has experience with both the US and European regulatory agencies. His depth of knowledge in our specific area of drug development along with a deep understanding of the regulatory requirements necessary for marketing authorization will be of great value in the upcoming months," said Dr. Mary Tagliaferri, Bionovo's President and Chief Medical Officer.

Dr. Pickar states, "I am very excited to join Bionovo's prestigious Medical Advisory Board to further advance one of the most promising drugs for women's health, Menerba. Bionovo's novel selective estrogen receptor beta agonist has shown great promise in Phase 2 clinical testing to safely and effectively treat hot flashes. If approved, Menerba will be in great demand by women seeking a safe and effective treatment for hot flashes."

Dr. James Pickar served as Assistant Vice President of Clinical Research and Development at Wyeth Research for over twelve years. Prior to that, Dr. Pickar held several other positions in Clinical Research and Development at Wyeth Research, dating back to 1985. Dr. Pickar is currently an Adjunct Associate Professor of Obstetrics and Gynecology at Columbia University, and he has served on the Board of Directors for the International Menopause Society since 2005. In addition, Dr. Pickar has over 25 years of clinical research experience. He has received numerous academic and scientific appointments and is author of over 65 papers published in peer reviewed international journals.

About Menerba

Menerba is an oral, botanically-derived drug candidate designed for the safe, effective treatment of vasomotor symptoms (hot flashes) associated with menopause. Menerba is an estrogen receptor beta (ERb) selective drug, developed as a safer alternative to the products currently on the market, which have been shown to increase the risk for breast and uterine cancers. Clinical tests conducted thus far, following the specific guidance of the FDA, have indicated that Menerba is effective and safe.

About Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit http://www.bionovo.com.

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.

SOURCE Bionovo, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
HemaQuest Pharmaceuticals Initiates Phase 2 Clinic...
S
Concerned Osteotech Stockholders Comment on Compan...